Comp Effectiveness Needed To Slow Spread Of New Technology – MedPAC
This article was originally published in The Gray Sheet
Executive Summary
Expanding federally funded comparative clinical effectiveness research is needed to slow use of costly but questionable new medical technology, the chairman of a congressional advisory group on Medicare told a House panel March 17